Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
SOMNOMED LIMITED (SOM)ASX AI Signals has generated 3 signal for SOM during the last 90 days, indicating active trading activity and ongoing AI monitoring
Latest SOM Signals | |
| 15/06/2026 | SELL |
| 14/06/2026 | SELL |
| 13/06/2026 | SELL |
SOM Share Price | |
| Current Price | $0.505 |
| 52 Week High | $0.890 |
| 52 Week Low: | $0.505 |
| Trading at (% of 52 Week High) | 56.74% |
SomnoMed Limited (ASX: SOM) is a medical device company that develops and distributes oral devices for the treatment of sleep apnea and snoring. Its products are designed to provide a non-invasive alternative to continuous positive airway pressure (CPAP) therapy. The company operates globally, serving dental and medical professionals.
The Health Care Equipment & Services sector on the ASX includes companies that produce medical devices, equipment, and supplies, as well as those providing healthcare-related services. This sector covers a wide range of products such as surgical instruments, diagnostic machines, and health monitoring devices. It also includes businesses involved in healthcare management, medical laboratories, and support services. These companies play a key role in supporting hospitals, clinics, and other healthcare providers to improve patient care. The sector is influenced by factors like technological advances, regulatory changes, and demand for healthcare services.
The SELL recommendation for SOMNOMED LIMITED is supported by moderate bearish signals, though some volatility and sector-specific factors introduce uncertainty. Caution is advised due to mixed market conditions.
SomnoMed Limited's (ASX:SOM) price-to-sales (or "P/S") ratio of 1x might make it look like a strong buy right now compared to the Medical Equipment industry in Australia, where around half of the companies have P/S ratios above 5.4x and even P/S above 16x are quite common. Nonetheless, we'd need to Generally speaking long term investing is the way to go. But that doesn't mean long term investors can avoid big losses. For example the SomnoMed Limited (ASX:SOM) share price dropped 60% over five years. We certainly feel for shareholders who bought near the top. And it's not just long term holders In the past three years, the share price of SomnoMed Limited (ASX:SOM) has struggled to grow and now shareholders are sitting on a loss. In addition, the company's per-share earnings growth is not looking good, despite growing revenues. In light of this performance, shareholders will have a chance t Looking at SomnoMed Limited's (ASX:SOM ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.
While we would never suggest that investors should base their decisions solely on what th PLANO, Texas, Oct. 28, 2022 /PRNewswire/ -- SomnoMed Limited (ASX "SOM", or the Company), a leading company in the provision of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea ('OSA'), is pleased to provide its quarterly activities report for the Latest SOMNOMED LIMITED(SOM) News
Revenues Working Against SomnoMed Limited's (ASX:SOM) Share Price
The past five years for SomnoMed (ASX:SOM) investors has not been profitable
Shareholders May Not Be So Generous With SomnoMed Limited's (ASX:SOM) CEO Compensation And Here's Why
A SomnoMed Limited (ASX:SOM) insider increased their holdings by 167% last year
SomnoMed's North America Q1 revenue growth leads the way
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial